Anxiety: Drugs That Cause It, Drugs That Treat It, and When to Act

What Is Anxiety as a Medical Symptom?

Anxiety is a subjective state of apprehension, physiologic arousal, and cognitive worry that can arise from psychiatric disorders, general medical conditions, or direct pharmacologic effects. Clinically, it spans a spectrum from normal adaptive stress responses to disabling generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias.

The Physiology Behind the Feeling

The core circuit involves the amygdala, the hypothalamic-pituitary-adrenal (HPA) axis, and norepinephrine pathways in the locus coeruleus. When these systems are overactivated, the body releases cortisol and catecholamines, producing palpitations, diaphoresis, tremor, and the subjective sense of dread most patients recognize as anxiety. A 2020 review in Neuropsychopharmacology confirmed that dysregulation of the serotonin transporter gene (SLC6A4) and corticotropin-releasing factor (CRF) receptor signaling both contribute to trait anxiety vulnerability. [1]

Anxiety as a Symptom Versus a Disorder

Anxiety as a standalone symptom differs from a formal anxiety disorder. Isolated anxiety lasting fewer than 6 months, clearly tied to a stressor or a drug exposure, does not meet criteria for GAD. DSM-5-TR requires at least 6 months of excessive worry on more days than not, plus three of six associated symptoms (restlessness, fatigue, concentration difficulty, irritability, muscle tension, sleep disturbance), causing functional impairment. [2]

Drugs That CAUSE Anxiety: The Key Offenders

Many prescription drugs, over-the-counter agents, and recreational substances produce anxiety as a direct pharmacologic effect, a withdrawal syndrome, or an indirect consequence of the drug's primary action. Identifying these agents can eliminate anxiety before any psychiatric treatment is needed.

Stimulants and Sympathomimetics

Beta-2 agonists such as albuterol increase circulating catecholamines and directly stimulate cardiac and CNS adrenergic receptors. Short-acting albuterol inhalers are among the most common drug-induced anxiety triggers seen in primary care. Prescription stimulants, including amphetamine salts (Adderall) and methylphenidate (Ritalin), produce anxiety in a dose-dependent manner. A 2019 analysis in JAMA Psychiatry found that among adults initiated on prescription stimulants for ADHD, 19.2% developed clinically significant new-onset anxiety symptoms within 12 weeks of starting therapy. [3]

Corticosteroids

Prednisone, dexamethasone, and methylprednisolone all modulate glucocorticoid receptors in the hippocampus and prefrontal cortex. Even short courses (5-14 days) can precipitate anxiety, irritability, or frank steroid psychosis. The risk scales with dose: daily prednisone doses above 40 mg carry roughly a 6% incidence of neuropsychiatric effects according to a cohort study published in Annals of Internal Medicine. [4]

Thyroid Hormone Preparations

Levothyroxine (Synthroid) and liothyronine (Cytomel) can induce anxiety when dosed above the patient's physiologic requirement. Any TSH value below 0.1 mIU/L in a patient on thyroid replacement should prompt clinical suspicion for medication-induced anxiety before initiating psychiatric treatment. The American Thyroid Association's 2014 guidelines explicitly flag palpitations and anxiety as signs of over-replacement. [5]

Caffeine-Containing and Decongestant Drugs

Caffeine at doses above 400 mg/day (roughly four standard 8-oz cups of coffee) antagonizes adenosine A1 and A2A receptors, directly increasing CNS arousal. Pseudoephedrine, phenylephrine, and similar decongestants share a mechanism with sympathomimetics and commonly worsen anxiety. The FDA's 2023 advisory panel vote against oral phenylephrine's efficacy should prompt prescribers to consider whether patients are taking it unnecessarily and experiencing adverse anxiogenic effects with no offsetting nasal benefit. [6]

Alcohol, Benzodiazepine, and Opioid Withdrawal

Paradoxically, benzodiazepines treat anxiety acutely but cause it on rebound. Inter-dose withdrawal from short-acting agents like alprazolam (Xanax, with a half-life of 6-27 hours) produces rebound anxiety that patients misread as their underlying disorder worsening. The same mechanism applies to alcohol withdrawal, where GABA-A receptor downregulation generates hyperexcitability. Opioid withdrawal activates noradrenergic hyperactivity in the locus coeruleus, producing profound anxiety as a cardinal symptom. [7]

Fluoroquinolone Antibiotics

Ciprofloxacin, levofloxacin, and related fluoroquinolones inhibit GABA-A receptor activity via their quinolone core. Case series and a 2021 pharmacovigilance study in Drug Safety documented anxiety, insomnia, and agitation in approximately 1.3% of fluoroquinolone-exposed patients, a rate 2.7 times higher than matched penicillin-exposed controls. [8]

First-Line Drugs That TREAT Anxiety

SSRIs: The Guideline-Recommended Starting Point

Selective serotonin reuptake inhibitors are the pharmacologic backbone of anxiety treatment across virtually every major guideline. The 2023 American Psychological Association Practice Guideline for Anxiety Disorders recommends SSRIs as initial pharmacotherapy for GAD, panic disorder, social anxiety disorder, and PTSD. [9]

Specific agents with the strongest trial evidence include:

• Escitalopram (Lexapro): In a 12-week RCT (N=429), escitalopram 10-20 mg reduced GAD Hamilton Anxiety Scale (HAM-A) scores by a mean of 14.2 points versus 10.5 for placebo (P<0.001). [10]
• Paroxetine (Paxil): FDA-approved for GAD, panic disorder, social anxiety disorder, and PTSD. Its short half-life makes it prone to discontinuation syndrome; use with caution.
• Sertraline (Zoloft): Particularly well-studied in panic disorder; a meta-analysis of 9 RCTs (N=2,234) found a number needed to treat (NNT) of 6.4 for panic-free response at 12 weeks. [11]

SSRIs typically require 4-6 weeks to produce meaningful anxiety reduction. Patients should be warned that the first 1-2 weeks may produce a transient increase in anxiety or insomnia, which resolves in most cases. Starting at half the target dose for the first 7 days reduces early-onset agitation.

SNRIs: A Close Second with Overlapping Indications

Serotonin-norepinephrine reuptake inhibitors are equally guideline-supported and offer the added benefit of treating comorbid pain conditions. Venlafaxine XR (Effexor XR) at 75-225 mg/day is FDA-approved for GAD, panic disorder, and social anxiety disorder. In the landmark trial by Gelenberg et al. (N=540, 24 weeks), venlafaxine XR produced remission (HAM-A below 7) in 42% of GAD patients versus 22% with placebo (P<0.001). [12]

Duloxetine (Cymbalta) at 60-120 mg/day is FDA-approved for GAD and carries additional evidence for generalized musculoskeletal pain, making it a preferred agent when anxiety co-occurs with chronic pain.

Buspirone: Dependence-Free but Slower

Buspirone (Buspar) is a partial 5-HT1A agonist and D2 receptor antagonist with no cross-tolerance to benzodiazepines and no abuse potential. At 15-60 mg/day in divided doses, it reduces GAD symptoms effectively. A Cochrane review (14 RCTs, N=1,805) found buspirone superior to placebo (standardized mean difference -0.41, 95% CI -0.57 to -0.26) for GAD with no difference in discontinuation rates compared to SSRIs. [13]

The critical clinical point: buspirone requires 2-4 weeks before any clinical benefit appears. Patients who have previously taken benzodiazepines often report buspirone "does not work" because they are comparing it to the immediate relief of a benzo. Setting realistic expectations upfront is essential.

Benzodiazepines: Effective, But Risky

Benzodiazepines, including diazepam, lorazepam, clonazepam, and alprazolam, enhance GABA-A receptor function and produce anxiolysis within 30-60 minutes. They remain the fastest-acting pharmacologic option and retain a clinical role in acute panic episodes and short-term situational anxiety (for example, procedural anxiety or air travel).

The risks are well-documented. Dependence develops in a significant proportion of patients using benzodiazepines daily for more than 4 weeks. A 2022 study in BMJ Open (N=12,438) found that 43% of patients prescribed benzodiazepines for anxiety remained on them at 12 months, far exceeding the 2-4 week guideline-recommended duration. [14] Cognitive impairment, fall risk in adults over 65, and respiratory depression in combination with opioids are additional concerns.

The FDA's 2020 black-box warning update requires labeling on all benzodiazepines to state the serious risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions. [15]

Current guidelines position benzodiazepines as adjunctive bridge therapy only, used for the first 2-4 weeks while an SSRI or SNRI reaches therapeutic effect, then tapered off.

Second-Line and Adjunctive Pharmacotherapy

Pregabalin

Pregabalin (Lyrica) at 150-600 mg/day in divided doses is approved in the European Union for GAD and is used off-label in the United States. A meta-analysis of 8 RCTs (N=2,299) showed pregabalin's NNT for GAD response was 5.0, similar to SSRIs, with faster onset (1-2 weeks versus 4-6 weeks). [16] Its Schedule V controlled substance classification reflects a modest abuse potential. It may be preferred when anxiety co-occurs with neuropathic pain or fibromyalgia.

Beta-Blockers for Situational Anxiety

Propranolol 10-40 mg taken 30-60 minutes before a performance or high-stress event reduces peripheral symptoms of anxiety (tremor, palpitations, sweating) without sedation. Propranolol does not treat the cognitive component of anxiety and has no role as a daily maintenance agent for GAD. Still, for performance anxiety specifically, it works well and has decades of supporting data. [17]

Hydroxyzine

Hydroxyzine (Vistaril) at 25-100 mg up to four times daily is an antihistamine with anxiolytic properties derived from H1 receptor blockade and 5-HT2A antagonism. It produces no dependence, has a half-life of 14-25 hours, and may be especially useful in patients with substance use history where benzodiazepines are contraindicated. A 2022 systematic review in Journal of Affective Disorders found hydroxyzine comparable to lorazepam for acute situational anxiety in a 4-week RCT. [18]

The HealthRX Anxiety Pharmacotherapy Decision Framework

Clinicians at HealthRX follow a structured decision pathway for new anxiety presentations:

1. Rule out drug-induced anxiety first. Review the full medication list against known anxiogenic agents (stimulants, steroids, thyroid hormone, decongestants, caffeine, fluoroquinolones) before initiating any psychiatric drug.
2. Order TSH, CBC, and metabolic panel. Hyperthyroidism, anemia, and hypoglycemia all produce anxiety symptoms that resolve with treatment of the underlying condition.
3. Administer GAD-7 at baseline. A score of 5-9 is mild, 10-14 moderate, 15-21 severe.
4. GAD-7 5-9: Start with psychotherapy referral plus lifestyle modification (aerobic exercise 150 minutes/week has an effect size of 0.48 versus control for anxiety reduction). [19]
5. GAD-7 10-14: Initiate an SSRI or SNRI, typically escitalopram 5-10 mg or sertraline 25-50 mg, and schedule a 2-week follow-up for tolerability.
6. GAD-7 15-21 or comorbid panic disorder: Consider adding hydroxyzine or a short benzodiazepine bridge (maximum 4 weeks) while the SSRI titrates; refer to psychiatry.
7. Buspirone substitution is appropriate when benzodiazepine dependence has developed or when the patient has a substance use disorder.
8. Reassess GAD-7 at 8 weeks. If the score has not dropped by at least 5 points, titrate dose or switch agents.

How Anxiety Is Diagnosed

Diagnosis combines validated screening tools, clinical interview, and exclusion of medical causes. The GAD-7 is the most widely used screening instrument. Scores of 10 or above show sensitivity of 89% and specificity of 82% for GAD in primary care populations, per the original validation study by Spitzer et al. In Archives of Internal Medicine (N=2,740). [20]

Differential Diagnosis: Medical Conditions That Mimic Anxiety

Conditions that must be excluded before a primary anxiety disorder diagnosis is assigned include:

• Hyperthyroidism (order TSH, free T4)
• Pheochromocytoma (order 24-hour urine catecholamines or plasma metanephrines in refractory cases)
• Hypoglycemia (fasting glucose, HbA1c)
• Cardiac arrhythmias, particularly paroxysmal supraventricular tachycardia
• Substance use and withdrawal
• Medication side effects (see above)

An elevated resting heart rate above 100 bpm, weight loss, or heat intolerance alongside anxiety should prompt thyroid evaluation before any psychiatric drug is started.

When to Worry: Red Flags That Require Immediate Action

Most anxiety disorders are managed outpatient, but certain presentations require urgent evaluation.

Chest pain with palpitations during a panic attack must be distinguished from acute coronary syndrome, particularly in adults over 40 or those with cardiovascular risk factors. The presentation overlaps substantially. Arrive at the emergency department rule-out before attributing chest pain to panic. A 2018 study in Annals of Emergency Medicine found that 4.1% of patients presenting with a chief complaint of panic attack had a serious cardiac or pulmonary cause identified during the same visit. [21]

Other situations that require escalation beyond primary care:

• Agoraphobia preventing the patient from leaving home
• Comorbid suicidal ideation (assess PHQ-9 alongside GAD-7)
• GAD-7 above 15 unresponsive to two adequate SSRI trials
• Suspected benzodiazepine dependence requiring supervised taper
• New-onset anxiety in a patient over 60 with no prior psychiatric history (consider organic cause)

The Role of Non-Drug Interventions Alongside Pharmacotherapy

Pharmacotherapy works best in combination with evidence-based psychotherapy. Cognitive behavioral therapy (CBT) produces effect sizes of 0.80-1.0 for GAD and panic disorder, comparable to medication, and its benefits persist longer after treatment ends. [22]

Aerobic exercise is not merely lifestyle advice. A meta-analysis of 15 RCTs in Frontiers in Psychiatry (N=1,112) found a standardized mean difference of 0.48 favoring exercise over passive control for anxiety symptoms. [19] Patients should aim for at least 150 minutes of moderate-intensity aerobic exercise per week, consistent with the 2018 U.S. Physical Activity Guidelines.

Mindfulness-based stress reduction (MBSR) demonstrated a non-inferior outcome to escitalopram at 8 weeks in the MAHA trial (N=276) published in JAMA Psychiatry in 2023, with remission rates of 52.7% for MBSR versus 57.2% for escitalopram (difference not statistically significant). [23]